When it comes to targeted cancer treatments, new biomarkers are continually found, and additional treatment options are approved. Keeping pace with those changes with MH Guide 5.2.
Noteworthy updates include:
- Regulatory agency information to focus on locally approved biomarkers
- Multiple variants can be simultaneously managed with just a few clicks
- Improved display of HRD and MSI scores